Literature DB >> 24222608

Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient.

Fabio Arena1, Tommaso Giani, Angelo Galano, Marcello Pasculli, Valeria Peccianti, Maria Iris Cassetta, Andrea Novelli, Gian Maria Rossolini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24222608      PMCID： PMC3837859          DOI： 10.1128/AAC.01112-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  6 in total

1.  In vitro activities in new oxazolidinone antimicrobial agents against enterococci.

Authors:  G M Eliopoulos; C B Wennersten; H S Gold; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

2.  Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia.

Authors:  Emmanuel Boselli; Dominique Breilh; Aurore Caillault-Sergent; Sarah Djabarouti; Christian Guillaume; Fabien Xuereb; Lionel Bouvet; Thomas Rimmelé; Marie-Claude Saux; Bernard Allaouchiche
Journal:  J Antimicrob Chemother       Date:  2012-02-20       Impact factor: 5.790

Review 3.  Linezolid in vitro: mechanism and antibacterial spectrum.

Authors:  David M Livermore
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

4.  Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.

Authors:  Craig R Rayner; Alan Forrest; Alison K Meagher; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Risk factors for a low linezolid trough plasma concentration in acute infections.

Authors:  Laura Morata; Marta Cuesta; Jhon F Rojas; Sebastian Rodriguez; Merce Brunet; Gregori Casals; Nazareth Cobos; Cristina Hernandez; José A Martínez; Josep Mensa; Alex Soriano
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

6.  Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.

Authors:  Chiara Adembri; Stefania Fallani; Maria Iris Cassetta; Silvia Arrigucci; Alessandra Ottaviano; Patrizia Pecile; Teresita Mazzei; Raffaele De Gaudio; Andrea Novelli
Journal:  Int J Antimicrob Agents       Date:  2007-12-04       Impact factor: 5.283
  6 in total
  3 in total

1.  Reply to "Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient".

Authors:  Laura Morata; Josep Mensa; Alex Soriano
Journal:  Antimicrob Agents Chemother       Date:  2013-12       Impact factor: 5.191

2.  What's New in the Treatment of Enterococcal Endocarditis?

Authors:  Masayuki Nigo; Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2014-10       Impact factor: 3.725

3.  Prevalence of vancomycin-variable Enterococcus faecium (VVE) among vanA-positive sterile site isolates and patient factors associated with VVE bacteremia.

Authors:  Philipp Kohler; Alireza Eshaghi; Hyunjin C Kim; Agron Plevneshi; Karen Green; Barbara M Willey; Allison McGeer; Samir N Patel
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.